First-in-Human Phase I Data for Insilico's AI-Designed Pan-TEAD Inhibitor ISM6331 to Be Presented at ESMO 2026

Summary

Rapid Oral presentation will report initial Phase I data for ISM6331 in patients with advanced solid tumors FDA Fast Track- and Orphan Drug-designated program reflects Insilico’s strategy to advance AI-designed medicines against difficult-to-treat, age-associated diseases CAMBRIDGE, Mass. — September 22, 2026 — Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today reminded the oncology community that initial Phase I data for ISM6331, its investigational pan-TEAD inhibitor, will be presented in a Rapid Oral session at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23–27 in Madrid, Spain. The presentation will provide the first reported clinical findings from the global, multicenter first-in-human study of ISM6331 in patients with advanced solid tumors. ISM6331 is designed to inhibit all four TEAD family transcription factors and disrupt tumor-promoting signals driven by dysregulation of the Hippo pathway, a central regulator of cell growth, survival, tissue homeostasis and regeneration. Presentation details Title: First-in-human Multicenter Phase 1 Study of ISM6331, an AI-Designed Pan-TEAD Inhibitor, in Patients with Mesothelioma or Other Advanced Solid Tumors Abstract number: #997 Session: Rapid Oral Presentation: Developmental Therapeutic Format: Rapid Oral presentation Presenter: Melina E. Marmarelis, MD, Hematology and Oncology, Abramson Cancer Center, University of Pennsylvania Date: Sunday, October 25, 2026 Time: 8:30–10:00 a.m. CEST Location: Cordoba Auditorium – Hall 4 “The ESMO presentation is an important opportunity to share the first clinical findings from ISM6331 with the global oncology community,” said Halle Zhang, PhD, Vice President, Clinical Development – Oncology at Insilico Medicine. “Patients with advanced mesothelioma and other Hippo pathway-dysregulated tumors have a significant unmet medical need. We look forward to presenting the emerging safety, pharmacokinetic and antitumor findings from this first-in-human study and discussing the next stage of the program.” From generative chemistry to clinical validation Insilico nominated ISM6331 as a preclinical candidate in June 2023. Its novel, non-covalent scaffold was generated with support from Chemistry42, the company’s generative chemistry platform, using structure-b…